Renerve Valuation Multiples

Discover revenue and EBITDA valuation multiples for Renerve and similar public comparables like Modne Zakupy, BibbInstruments, Scandinavian ChemoTech, Spineguard and more.

Renerve Overview

About Renerve

Renerve Ltd specializes in developing a range of ready-to-use products that are cleaner, safer for repairing or replacing damaged peripheral nerves, resulting in good patient outcomes. Its product candidates include NervAlign Bionic Nerve, NervAlign Nerve Graft, and NervAlign Nerve Cuff [The NervAlign Nerve Guide Matrix, The NervAlign Nerve Conduit, The NervAlign Bionic Replacement Nerve]. The company operates in New Zealand and USA. Maximum of revenue is from USA.


Founded

2016

HQ

Australia

Employees

N/A

Financials (FY)

Revenue: $190K
EBITDA: ($2M)

EV

$7M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Renerve Financials

Renerve reported last fiscal year revenue of $190K and negative EBITDA of ($2M).

In the same fiscal year, Renerve generated $171K in gross profit, ($2M) in EBITDA losses, and had net loss of ($3M).


Renerve P&L

In the most recent fiscal year, Renerve reported revenue of $190K and EBITDA of ($2M).

Renerve is unprofitable as of last fiscal year, with gross margin of 90%, EBITDA margin of (1265%), and net margin of (1374%).

See analyst estimates for Renerve
Last FY202320242025202620272028
Revenue$190K$107K$157K$190K
Gross Profit$171K$107K$147K$171K
Gross Margin90%100%94%90%
EBITDA($2M)($1M)($2M)($2M)
EBITDA Margin(1265%)(1371%)(1332%)(1265%)
EBIT Margin(1639%)(1737%)(1686%)(1639%)
Net Profit($3M)($2M)($2M)($3M)
Net Margin(1374%)(1565%)(1496%)(1374%)

Financial data powered by Morningstar, Inc.

Renerve Stock Performance

Renerve has current market cap of $10M, and enterprise value of $7M.

Market Cap Evolution


Renerve's stock price is $0.06.

Renerve share price increased by 5.5% in the last 30 days, and decreased by 18.0% in the last year.

Renerve has an EPS (earnings per share) of $-0.02.

See more trading valuation data for Renerve
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$7M$10M-0.2%5.5%-22.7%-18.0%$-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Renerve Valuation Multiples

Renerve trades at 35.9x EV/Revenue multiple, and (2.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Renerve

Renerve Financial Valuation Multiples

As of July 19, 2026, Renerve has market cap of $10M and EV of $7M.

Renerve has a P/E ratio of (3.7x).

Last FY202320242025202620272028
EV/Revenue35.9x63.8x43.5x35.9x
EV/EBITDA(2.8x)(4.7x)(3.3x)(2.8x)
EV/EBIT(2.2x)(3.7x)(2.6x)(2.2x)
EV/Gross Profit39.9x64.0x46.3x39.9x
P/E(3.7x)(5.8x)(4.1x)(3.7x)
EV/FCF(3.2x)(5.1x)(3.7x)(3.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Renerve Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Renerve Margins & Growth Rates

In the most recent fiscal year, Renerve reported gross margin of 90%, EBITDA margin of (1265%), and net margin of (1374%).

See estimated margins and future growth rates for Renerve

Renerve Margins

Last FY20242025202720282029
Gross Margin90%94%90%
EBITDA Margin(1265%)(1332%)(1265%)
EBIT Margin(1639%)(1686%)(1639%)
Net Margin(1374%)(1496%)(1374%)
FCF Margin(1122%)(1191%)(1122%)

Renerve Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth47%21%
Gross Profit Growth38%16%
EBITDA Growth43%15%
EBIT Growth42%18%
Net Profit Growth40%11%
FCF Growth40%14%

Data powered by FactSet, Inc. and Morningstar, Inc.

Renerve Operational KPIs

Access forward-looking KPIs for Renerve
Last FY202320242025202620272028
S&M Expenses to Revenue155%256%193%155%
G&A Expenses to Revenue908%1051%940%908%
R&D Expenses to Revenue368%350%395%368%
Opex to Revenue1729%1837%1780%1729%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Renerve Competitors

Renerve competitors include Modne Zakupy, BibbInstruments, Scandinavian ChemoTech, Spineguard, Truscreen Group, Clinical Laserthermia, Co-Diagnostics, iXensor, Iconovo and Nestmedic.

Most Renerve public comparables operate across Medical Devices.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Modne Zakupy8724.9x-(113.3x)-
BibbInstruments226.1x-(6.9x)-
Scandinavian ChemoTech-5.7x-(40.4x)
Spineguard2.0x2.2x(7.0x)(8.1x)
Truscreen Group6.0x-(6.5x)-
Clinical Laserthermia4.1x3.0x(2.7x)(2.9x)
Co-Diagnostics4.6x4.6x(0.1x)-
iXensor10.5x-(7.1x)-

This data is available for Pro users. Sign up to see all Renerve competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Renerve

When was Renerve founded?Renerve was founded in 2016.
Where is Renerve headquartered?Renerve is headquartered in Australia.
Is Renerve publicly listed?Yes, Renerve is a public company listed on Australian Securities Exchange.
What is the stock symbol of Renerve?Renerve trades under RNV ticker.
When did Renerve go public?Renerve went public in 2024.
Who are competitors of Renerve?Renerve main competitors include Modne Zakupy, BibbInstruments, Scandinavian ChemoTech, Spineguard, Truscreen Group, Clinical Laserthermia, Co-Diagnostics, iXensor, Iconovo, Nestmedic.
What is the current market cap of Renerve?Renerve's current market cap is $10M.
What is the current revenue of Renerve?Renerve's last fiscal year revenue is $190K.
What is the current EV/Revenue multiple of Renerve?Current revenue multiple of Renerve is 35.9x.
Is Renerve profitable?No, Renerve is not profitable.
How many companies Renerve has acquired to date?Renerve hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Renerve has invested to date?Renerve hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Renerve

Lists including Renerve

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial